Journal of Diagnostics Concepts & Practice >
Interpretation of clinical practice guidelines for myelodysplastic syndrome (version 1, 2023) of National Comprehensive Cancer Nerwork(NCCN)
Received date: 2022-11-15
Online published: 2023-08-31
Myelodysplastic syndrome (MDS) is a diverse and common group of myeloid malignant clonal diseases in the hematologic system, with different classification and grouping, clinical manifestations and natural course, and the iteration of different classification systems and versions in history, resulting distress in the correct diagnosis, classification and treatment options. The National Comprehensive Cancer Network (NCCN) released the first version （2023） of Clinical Practice Guidelines for MDS in September 2022. The guideline is based on the clinical practice and standards of high-level evidence and the latest research progress, and its attracts wide attention from clinicians worldwide. Currently, many clinicians in China have insufficient understanding of MDS, and there is still a certain gap with the international diagnosis and treatment level of MDS. This paper interprets the content of the new guidelines, and compares it with the previous guidelines, in order to provide a reference for the standardized diagnosis and treatment of MDS at the current stage in China.
Key words： Myelodysplastic syndrome; Diagnosis; Prognosis; Guideline; Interprelation
SONG Luqian, CHANG Chunkang . Interpretation of clinical practice guidelines for myelodysplastic syndrome (version 1, 2023) of National Comprehensive Cancer Nerwork(NCCN)[J]. Journal of Diagnostics Concepts & Practice, 2023 , 22(02) : 116 -120 . DOI: 10.16150/j.1671-2870.2023.02.002
| [1] | CAZZOLA M. Myelodysplastic Syndromes[J]. N Engl J Med, 2020, 383(14):1358-1374. |
| [2] | NCCN. Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes, version1. 2023[R/OL]. 2023[2022-11-21]. https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. |
| [3] | KHOURY J D, SOLARY E, ABLA O, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms[J]. Leukemia, 2022, 36(7):1703-1719. |
| [4] | ARBER D A, ORAZI A, HASSERJIAN R P, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data[J]. Blood, 2022, 140(11):1200-1228. |
| [5] | BERNARD E, TUECHLER H, GREENBERG P L, et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes[J/OL]. NEJM Evid, 2022 [2022-11-21]. https://evidence.nejm.org/doi/10.1056/EVIDoa2200008. |
| [6] | GREENBERG P L, TUECHLER H, SCHANZ J, et al. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes[J]. Blood, 2016, 128(16):2096-2097. |
| [7] | DELLA PORTA M G, TRAVAGLINO E, BOVERI E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes[J]. Leukemia, 2015, 29(1):66-75. |
| [8] | CHEN X, FROMM J R, NARESH K N. "Blasts" in myeloid neoplasms - how do we define blasts and how do we incorporate them into diagnostic schema moving forward?[J]. Leukemia, 2022, 36(2):327-332. |
| [9] | ESTEY E, HASSERJIAN R P, D?HNER H. Distinguis-hing AML from MDS: a fixed blast percentage may no longer be optimal[J]. Blood, 2022, 139(3):323-332. |
| [10] | GREENBERG P L, TUECHLER H, SCHANZ J, et al. Revised international prognostic scoring system for mye-lodysplastic syndromes[J]. Blood, 2012, 120(12):2454-2465. |
| [11] | MARGOLSKEE E, HASSERJIAN R P, HASSANE D, et al. Myelodysplastic syndrome, unclassifiable (MDS-U) with 1% blasts is a distinct subgroup of MDS-U with a poor prognosis[J]. Am J Clin Pathol, 2017, 148(1):49-57. |
| [12] | BERSANELLI M, TRAVAGLINO E, MEGGENDORFER M, et al. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes[J]. J Clin Oncol, 2021, 39(11):1223-1233. |
/
| 〈 |
|
〉 |
